{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-091936","form_type":"8-K","ticker":null,"cik":"0001626199","company_name":"ALPINE IMMUNE SCIENCES, INC.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.307602+00:00","generated_at":"2026-06-04T00:25:14.352048+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Vertex to acquire Alpine for $65/share (~$4.9B); deal expected to close Q2 2024","bullets":["Total equity value ~$4.9B; Vertex will pay $65 per share in cash.","Alpine’s lead drug povetacicept (dual BAFF/APRIL antagonist) showed best-in-class potential in IgA nephropathy; Phase 3 planned H2 2024.","Stockholders owning ~25.5% of shares have agreed to tender; termination fee of $173M payable by Alpine under certain conditions.","Transaction unanimously approved by both boards; expected to close in Q2 2024, subject to HSR and tender of majority of shares.","Alpine’s pipeline includes studies in membranous nephropathy, lupus nephritis, and autoimmune cytopenias."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-091936","json":"https://secwatch.observer/filing/0001193125-24-091936.json","markdown":"https://secwatch.observer/filing/0001193125-24-091936.md","text":"https://secwatch.observer/filing/0001193125-24-091936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/0001193125-24-091936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/d820872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:25:14.352048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea331a91025086093ec557db77c469b90825df0c","claim":"ALPINE IMMUNE SCIENCES, INC. entered into Agreement and Plan of Merger with Vertex Pharmaceuticals Incorporated valued at $65.00 per share in cash, aggregate termination fee of $173 million (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626199/000119312524091936/0001193125-24-091936-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Vertex Pharmaceuticals Incorporated"},{"label":"Value","value":"$65.00 per share in cash, aggregate termination fee of $173 million"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}